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Change in longitudinal trends in sleep quality and duration
following breast cancer diagnosis: results from the Women’s
Health Initiative
Chloe M. Beverly1, Michelle J. Naughton2, Michael L. Pennell3, Randi E. Foraker4, Gregory Young5, Lauren Hale6,
Elizabeth M. Cespedes Feliciano 7, Kathy Pan8, Tracy E. Crane9, Suzanne C. Danhauer10 and Electra D. Paskett11
Breast cancer survivors frequently report sleep problems, but little research has studied sleep patterns longitudinally. We examined
trends in sleep quality and duration up to 15 years before and 20 years after a diagnosis of breast cancer, over time among
postmenopausal women participating in the Women’s Health Initiative (WHI). We included 12,098 participants who developed
invasive breast cancer after study enrollment. A linear mixed-effects model was used to determine whether the time trend in sleep
quality, as measured by the WHI Insomnia Rating Scale (WHIIRS), a measure of perceived insomnia symptoms from the past
4 weeks, changed following a cancer diagnosis. To examine sleep duration, we ﬁt a logistic regression model with random effects
for both short (<6 h) and long (≥9 h) sleep. In addition, we studied the association between depressive symptoms and changes in
WHIIRS and sleep duration. There was a signiﬁcantly slower increase in the trend of WHIIRS after diagnosis (β= 0.06; p= 0.03), but
there were non-signiﬁcant increases in the trend of the probability of short or long sleep after diagnosis. The probability of
depressive symptoms signiﬁcantly decreased, though the decrease was more pronounced after diagnosis (p < 0.01). Trends in
WHIIRS worsened at a relatively slower rate following diagnosis and lower depression rates may explain the slower worsening in
WHIIRS. Our ﬁndings suggest that over a long period of time, breast cancer diagnosis does not adversely affect sleep quality and
duration in postmenopausal women compared to sleep pre-diagnosis, yet both sleep quality and duration continue to worsen over
time.
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INTRODUCTION
Breast cancer is the most common cancer diagnosis in women.1
Breast cancer survivors report sleep problems, including poor sleep
quality, poor sleep efﬁciency, and sleep disturbance,2 as one of their
top ﬁve most burdensome long-term health issues.3 Compared to
women without cancer, breast cancer survivors are twice as likely to
experience sleep problems, and prior studies demonstrated that
20–90% report sleep disturbances, depending on the study
assessment method.3–6 Sleep problems may contribute to poorer
quality of life and health status among survivors.
Sleep changes in women with breast cancer can begin shortly
after diagnosis7 or during initial treatment with chemotherapy or
radiation therapy and may become chronic.8 Chemotherapy has
been shown to disrupt circadian rhythms9 and increase meno-
pausal symptoms, which in turn impact sleep quality and
quantity.10 In one of the few longitudinal studies on this topic,
researchers found that some sleep problems, such as inadequate
duration and lack of restorative sleep, resolve soon after the short-
term stressors of a cancer diagnosis and active treatment are
completed, but other sleep problems that originally stem from
cancer-related issues (such as treatments) persist.11 Little is known
about the longer term health effects of sleep disturbance on
breast cancer survivors.12
Currently, there are limited longitudinal data on sleep problems of
breast cancer survivors in older adults by various ages. Well-
documented changes in sleep structure, sleep quality, and sleep
timing are associated with increasing age13 and the highest rates of
insomnia are in postmenopausal women.14,15 Among older women
in good health with no insomnia complaints, there are more
awakenings during sleep than among younger adults.16 In general,
individuals can expect more disturbed sleep with age, including
frequent awakenings, early morning awakenings, and increased
daytime napping. However, individuals with comorbid conditions
have more exacerbated sleep changes than those in good health.17
Three papers have been published on breast cancer and sleep
using data from the Women’s Health Initiative (WHI), a national
longitudinal cohort study of postmenopausal women.18–20
Researchers found no association between self-reported sleep
Received: 18 December 2017 Revised: 15 May 2018 Accepted: 17 May 2018
1Division of Epidemiology, College of Public Health, The Ohio State University, Columbus, OH 43210, USA; 2Division of Population Sciences, Department of Internal Medicine,
College of Medicine, The Ohio State University, Columbus, OH 43210, USA; 3Division of Biostatistics, College of Public Health, The Ohio State University, Columbus, OH 43210,
USA; 4Institute for Informatics, School of Medicine, Washington University in St. Louis, St. Louis, MO 63108, USA; 5Center for Biostatistics, The Ohio State University, Columbus, OH
43210, USA; 6Program in Public Health, Department of Family, Population, and Preventive Medicine, Stony Brook University, Stony Brook, NY 11794, USA; 7Kaiser Permanente
Northern California Division of Research, Oakland, CA 94612, USA; 8Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, University of California, Los
Angeles, Torrance, CA 90509, USA; 9College of Nursing, University of Arizona Cancer Center, University of Arizona, Tucson, AZ 85724, USA; 10Department of Social Sciences and
Health Policy, Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA and 11Division of Cancer Prevention and Control, Department of
Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH 43210, USA
Correspondence: Chloe M. Beverly (chloe.beverly@osumc.edu)
www.nature.com/npjbcancer
Published in partnership with the Breast Cancer Research Foundation
duration, sleep quality, insomnia, or sleep disturbance and risk of
breast cancer.18 In relation to cancer survival, short sleep
combined with frequent snoring was negatively associated with
breast cancer survival,19 and more aggressive breast cancer
tumors were seen in women with shorter sleep duration and
poorer quality sleep.20 These prior research studies, however, do
not identify how sleep patterns may change over long periods of
time following a breast cancer diagnosis. The present study uses
WHI longitudinal data to examine sleep measures spanning up to
15 years before and 20 years after a breast cancer diagnosis. The
objective of this study was to determine whether trends in sleep
quality and duration changed after cancer diagnosis among
12,098 women in the WHI diagnosed with invasive breast cancer
after enrollment. Since the relationship between depression and
sleep has been well-established,21–23 we also considered this
important to explore.
RESULTS
Demographics
Baseline characteristics of the study population are listed in Table
1. A majority of women were non-Hispanic White (87.4%), enrolled
into WHI at ages 60–69 (46.7%), and were part of the WHI
observational study (OS) (58.3%). The mean age at breast cancer
diagnosis was 70.3 years and localized breast cancer was the most
common stage at diagnosis (74.8%). About 10% of women had
Burnam scores above the cutoff for depressive symptomology
(≥0.06). The average number of sleep measures per woman was
2.9 (range: 1–8). At WHI baseline, women had an average WHIIRS
sleep quality score of 6.5 and about 30% of women self-reported
insomnia symptoms. There were 18.4% of women in the highest
insomnia severity category. Most women slept between 7 and 8 h
per night (62.6%). The prevalence of short (<6 h) and long (≥9 h)
sleep duration was 7.0 and 4.4%, respectively.
Comparison of sleep patterns by race/ethnicity
Both baseline WHIIRS sleep quality score (p= 0.02) and duration
(p < 0.01) differed by race/ethnicity (Table 2). American Indian/
Alaskan Natives and non-Hispanic white women had the highest
mean baseline WHIIRS scores at 6.6, while Asian/Paciﬁc Islanders
had the lowest mean baseline WHIIRS score of 5.6 points. Black/
African Americans had the greatest proportion of women sleeping
<6 h per night at baseline (19.6%). American Indian/Alaskan
Natives had the lowest proportion of women sleeping between 7
and 8 h (35.1%) and also the highest proportion sleeping ≥9 h
(8.1%). Baseline insomnia symptoms did not differ by race/
ethnicity (p= 0.11).
Comparison of sleep patterns by age at enrollment
WHIIRS scores differed by age group (p < 0.01), with the highest
scores observed among women aged 70–79 years (mean= 6.9)
and the lowest among women aged 50–54 years (mean= 6.3, see
Table 2). Baseline insomnia symptoms and sleep duration also
differed by age group (p < 0.01 for each test), with women aged
70–79 years the most likely group to experience insomnia
symptoms (32.5%), sleep <6 h per night (7.7%), and to sleep
≥9 h (5.2%). Women aged 60–69 years had the highest proportion
of women sleeping between 7 and 8 h (63.7%).
Change in longitudinal trend in WHIIRS sleep quality
Data from these WHI participants were available for up to 15 years
before and 20 years after breast cancer diagnosis. The linear mixed
model estimated a mean WHIIRS score at breast cancer diagnosis
of 7.23 points (95% CI: 7.14–7.32). This is below the 9-point cutoff
for insomnia, but still indicates frequent sleep disturbance over
the last month. There was a signiﬁcant change in trend of WHIIRS
Table 1. Baseline demographic, clinical, and sleep variables of study
population
All participants n=
12,098a
Demographic factors
Race, n (%)
American Indian/Alaskan Native 37 (0.3)
Asian/Paciﬁc Islander 256 (2.1)
Black or African American 841 (7.0)
Hispanic/Latina 282 (2.3)
Non-Hispanic white 10,555 (87.4)
Other 104 (0.9)
Age at enrollment (years), n (%)
50–54 1548 (12.8)
55–59 2529 (20.9)
60–69 5651 (46.7)
70–79 2370 (19.6)
Trial arm, n (%)
Clinical trial 5051 (41.7)
Observational study 7047 (58.3)
Clinical factors
Age at BC diagnosis (years), mean (SD) 70.3 (7.8)
Years in WHI until BC diagnosis, mean (SD) 7.9 (5.0)
First sleep measure following BC diagnosis
(in years), mean (SD)
5.8 (4.4)
Stage of cancer, n (%)
Localized 7199 (74.8)
Regional 2180 (22.7)
Distant 141 (1.5)
Unknown 106 (1.1)
Medications for sleep, n (%)
Not in past 4 week 9212 (76.1)
Less than once per week 1149 (9.5)
1–2 times per week 674 (5.6)
3–4 times per week 279 (2.3)
5+ times per week 784 (6.5)
Depressive symptomology, n (%) (Burnam
scale cutoff, 0.06)
1150 (9.7)
Sleep factors
WHIIRS score, mean (SD) 6.5 (4.4)
Insomnia (≥9), n (%) 3572 (29.5)
Insomnia severity, n (%)
0 (0–3) 3383 (28.0)
1 (4–6) 3383 (28.0)
2 (7–10) 3110 (25.7)
3 (≥11) 2222 (18.4)
Sleep duration, n (%)
≤5 h 849 (7.0)
6 h 3149 (26.0)
7 h 4737 (39.2)
8 h 2832 (23.4)
≥9 h 531 (4.4)
aNot all participants answered every question
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score after diagnosis (β-interaction=−0.02, 95% CI: −0.04–
−0.002, t(6182)=−2.17, p-interaction= 0.03; see Fig. 1). Before
diagnosis, the score was increasing at 0.08 points per year (95% CI:
0.07–0.09, t(5490)= 16.88, p < 0.01), and after diagnosis the score
was still increasing, but at a slower rate of 0.06 points per year
(95% CI: 0.05–0.07, t(3900)= 9.31, p < 0.01). The change in trend of
WHIIRS score after breast cancer diagnosis did not differ
signiﬁcantly by race/ethnicity, age at diagnosis, cancer stage at
diagnosis, education level, income level, BMI category, marital
status, physical activity, and alcohol drinking (Holm’s corrected p-
values all >0.8).
Change in longitudinal trend in sleep duration
The probability of short sleep, <6 h (Fig. 2a), and long sleep, ≥9 h
(Fig. 2b), were increasing prior to breast cancer diagnosis and did
not signiﬁcantly change following diagnosis (short sleep: β-
interaction=−0.01, 95% CI: −0.04–0.01, z=−1.05, p-interaction
= 0.29; long sleep: β-interaction= 0.01, 95% CI: −0.02–0.04, z=
0.80, p-interaction= 0.43). There was also no signiﬁcant difference
in change in trend of the probability of short or long sleep
following diagnosis across race/ethnicity, age at diagnosis, cancer
stage, and all other demographic variables tested (Holm’s
corrected p-values all >0.5).
Change in depressive symptoms
We investigated the trend in depressive symptoms by number of
years since diagnosis and found the trend changed following
breast cancer diagnosis (β-interaction=−0.04, 95% CI: −0.06–
−0.01, z=−1.05, p-interaction <0.01). Prior to breast cancer
diagnosis, there was a slight decreasing trend in the probability of
depressive symptoms over time, but following diagnosis the
probability of depressive symptoms decreased more rapidly, from
9.5% at diagnosis to only 6% about 20 years after diagnosis (Fig.
3). We also adjusted for depressive symptoms as a time-varying
covariate in the WHIIRS sleep quality score model. When
depressive symptoms were included, the time by period interac-
tion was no longer statistically signiﬁcant (β-interaction=−0.01,
95% CI: −0.03–0.01, t(6033)=−1.24, p-interaction= 0.22). This
suggests that the changes in depressive symptoms may explain
the change in the longitudinal trend in sleep quality.
Sensitivity analysis
The results of the sensitivity analysis restricted to women with
measures at both pre- and post-diagnosis time points were similar
to the main results (all women, regardless of sleep measure time
points), and thus the conclusions remained the same.
DISCUSSION
This study examined the change in longitudinal trends of sleep
quality and sleep duration following breast cancer diagnosis
among breast cancer survivors. Our ﬁndings demonstrated that
the trend in sleep quality does signiﬁcantly change following
diagnosis; however, there were no statistically signiﬁcant changes
for sleep duration. We were unable to compare our study ﬁndings
to other ﬁndings that most women’s breast cancer-related sleep
problems resolve within a few years of diagnosis and treatment,11
given that our sleep data were on average 5.8 years after
diagnosis. As a result, we may be missing immediate changes in
sleep patterns following diagnosis. Due to the lengthy follow-up
times post diagnosis, this paper focused on assessing long-term
trends.
We found that sleep quality continues to worsen after
diagnosis, but at a slower rate than before. An increase of 0.08
points per year before diagnosis to an increase of 0.06 points per
year after diagnosis is a small change in sleep disturbance. WhileT
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this is likely not clinically signiﬁcant in 1-year increments, breast
cancer survivors are now living many years after their diagnosis.
Over longer time periods, increases in sleep disturbance may
become more troublesome. Short sleep and other symptoms of
poor sleep quality, including snoring, before diagnosis have been
previously associated with breast cancer survival.19 These
symptoms in our study continued to worsen following diagnosis,
suggesting that sleep is an important health behavior to address
in survivorship care.
We also hypothesized that the change in the trend of sleep
quality and duration would differ when stratiﬁed by subgroups
(race/ethnicity, age at diagnosis, cancer stage at diagnosis,
education level, income level, BMI category, marital status,
physical activity, and alcohol drinking). However, there were no
statistically signiﬁcant differences in the change in trend after
diagnosis for each subgroup. An earlier WHI study found minimal
variation in insomnia complaints due to age, race/ethnicity,
exercise, cigarette, alcohol, and coffee consumption, income,
employment, and marital status.16 A 2011 study11 investigated
longitudinal sleep duration changes early in breast cancer
survivorship and also had null ﬁndings by demographic and
clinical variables. Prior studies23–25 demonstrated differences
between sleep quality and duration by demographic variables,
such as age and sociodemographic factors yet most of these
studies were cross-sectional and did not examine differences in
longitudinal trends, which suggests the need for more long-
itudinal studies to fully understand subgroup differences. The role
of race/ethnicity in sleep may be very complex and could range
from the biological (e.g., genetic differences, comorbidity burden)
to the sociodemographic (e.g., work schedules, home environ-
ment, neighborhood deprivation).26 Unfortunately we did not
assess all of these variables in the current study.
The probability of women having short sleep increased post-
diagnosis, but the change was smaller than hypothesized based
on the supporting literature.5 WHI sleep assessments were not
collected frequently enough to observe changes in sleep which
may have occurred close to diagnosis. Also, women susceptible to
short sleep may already be experiencing poor sleep before
diagnosis. Insomnia was present in 30% of the sample at baseline,
which is much higher than the estimated 10% of the US
population but consistent with some estimates in postmenopau-
sal women.14,15
While counter to our initial hypothesis, the decrease in the
probability of depressive symptoms is similar to results from
another study.27 A 5-year observational study observed 48% of
women were depressed in the ﬁrst year after diagnosis and
decreased to 15% in the ﬁfth year of follow-up.28 This same study
also observed patient factors, such as younger age at diagnosis
and lack of social support, increased the risk of depression more
than the disease or treatment-speciﬁc factors. Women in our study
were older at diagnosis which could explain the lower level of
depressive symptoms after diagnosis. This resulting decrease in
depressive symptoms also resulted in smaller changes in sleep
disturbance.
The population of older adults in the US is growing rapidly and
health care systems are predicting increasing numbers of cancer
Fig. 1 Overall trend in WHIIRS sleep score by years from diagnosis
with 95% conﬁdence interval bounds. There was a signiﬁcant
change in trend of WHIIRS score after diagnosis (p-interaction=
0.03). Before diagnosis, the score was increasing (p-interaction <
0.01) at 0.08 points per year and after diagnosis the score was still
increasing (p-interaction < 0.01), but at a slower rate of 0.06 points
per year. Vertical center line indicates breast cancer diagnosis time
point.
Fig. 2 a Sleep duration—overall probability of <6 h sleep by years
from diagnosis. Prior to diagnosis, the estimated probability of short
sleep increased from 6% at 20 years prior to 9% at diagnosis.
Following diagnosis, the probability increased at a slower rate, and
only increased to 11% about 20 years after diagnosis (p= 0.29).
Vertical center line indicates breast cancer diagnosis time point. b
Sleep duration—overall probability of ≥9 h sleep by years from
diagnosis. Prior to diagnosis the estimated probability of long sleep
increased from 3% at 20 years prior to 6% at diagnosis. The
probability increased at a faster rate after diagnosis to 15% about 20
years after diagnosis (p= 0.43). Vertical center line indicates breast
cancer diagnosis time point.
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diagnoses.29 Almost 50% of new breast cancer cases are
diagnosed in women between the ages of 55 and 74 years.1
Older cancer survivors, often with comorbid conditions, will have
complex needs and will be the focus of cancer control and
prevention efforts.30 Breast cancer survivors currently comprise 3
million US women and 5-year survival rates are as high as 89%.
Thus, it is important to know more about the projected health of
aging women, including sleep.
There are some limitations to this research. The participants in
this study were survivors of breast cancer, and there could be
differences, such as severity of disease or age at diagnosis,
between the women who did and did not survive (n= 2716;
22.4%) during follow-up. Therefore, the smaller effect sizes we
observed may be due, in part, to survival bias. Sleep quality and
duration were also measured at variable times in relation to cancer
diagnosis. Some women had measures closer to their breast
cancer diagnosis, whereas others were assessed later in their
survivorship when they were no longer undergoing treatment
and/or experiencing many other cancer-related stressors. We did
not have complete data on the participants’ cancer treatment, but
sleep quality changes may be related to the type, timing, and
effects of cancer treatment8,9 so future research should include
these variables when possible. If sleep patterns had been assessed
more frequently in WHI, it is possible we may have captured
nonlinear trends due to temporary shifts in sleep patterns
immediately following breast cancer diagnosis and during
treatment. Finally, sleep assessments were self-reported and we
lacked an objective sleep measure, such as polysomnography or
actigraphy.31,32 Nevertheless, self-report remains a cost effective
and frequently used source of population sleep data.33,34
Strengths of this study are its uniqueness in reporting longer-
term trends up to 20 years after diagnosis. Other researchers have
highlighted the lack of longitudinal sleep data on women.12
Further, few research studies consider more than one aspect of
sleep and we examined both self-reported sleep quality and sleep
duration. Also, the large sample size and generalizability of our
results, given that the WHI sample are from 40 US clinical centers
representing data from many racial/ethnic minorities, are major
strengths. This study focused on within-survivor differences, but
future research using cancer-free controls will only further
elucidate the longer term sleep impact on survivors. By examining
changes in trends following diagnosis, we are able to look at
whether a breast cancer diagnosis affects the underlying natural
aging effect. Studying the effects of aging on longitudinal sleep
patterns in healthy older women, as opposed to those with a
cancer diagnosis, will be an important addition to this area of
research.
In summary, our study ﬁndings suggest sleep quality and
duration in postmenopausal women are likely not affected by a
breast cancer diagnosis over a long period of time compared to
their sleep before diagnosis. However, both sleep quality and
duration do clearly continue to worsen over time. Sleep habits
prior to diagnosis rather than the cancer diagnosis itself appear to
dictate the longitudinal trend of sleep. The American Cancer
Society/American Society of Clinical Oncology Breast Cancer
Survivorship Care Guideline outlines recommendations for mon-
itoring for adverse post-treatment symptoms, such as disturbed
sleep.35 The guideline recommends that primary care clinicians
treat sleep disturbance to help combat cancer-related fatigue.
Sleep is modiﬁable and can be improved by behavioral changes,
therapy, and pharmacotherapy when needed, which makes sleep
an appealing area to target for improving patient quality of life.36
Our analysis adds to the understanding of complex long-term
changes in sleep trends among breast cancer survivors. Based on
these ﬁndings, pre-existing sleep problems will be an important
variable for tailoring survivor care plans. Addressing sleep quality
and duration is important in improving the health-related quality
of life and general health of all breast cancer survivors.
METHODS
The WHI is a longitudinal study of 161,809 post-menopausal women that
began in 1993 and recruited from 40 clinical centers across the US. Women
were enrolled in either the WHI clinical trials (CT), which consisted of three
overlapping components (hormone therapy, dietary modiﬁcation, calcium,
and vitamin D supplementation), or the OS. Details of the study designs
and recruitment procedures are described elsewhere.37 At enrollment,
women were between the ages of 50–79 years. All participants provided
written informed consent and Institutional Review Boards of the
participating WHI sites approved the study protocols.
The main outcome measure for this study was the Women’s Health
Initiative Insomnia Rating Scale (WHIIRS).38,39 The WHIIRS, a measure of
perceived insomnia symptoms, consists of ﬁve questions that assess
insomnia and sleep quality during the past 4 weeks: “Did you have trouble
falling asleep?”; “Did you wake up several times at night?”; “Did you wake
up earlier than you planned to?”; “Did you have trouble getting back to
sleep after you woke up too early?”; and “Overall, was your typical night’s
sleep during the past 4 weeks: Very sound or restful, sound or restful,
average quality, restless, or very restless?” Response categories for these
items range from 0 (“No, not in the past 4 weeks”) to 4 (“Yes, 5 or more
times a week”), with a summed sleep quality score of the 5 items ranging
from 0 to 20. A higher WHIIRS score indicates poorer sleep quality. A
WHIIRS score of ≥9 is used as a cutoff for insomnia, since women scoring at
or above a 9 have scores consistent with a diagnosis of insomnia.38,39 In
addition, four insomnia severity categories were also formed from WHIIRS
scores based on score grouping by previous studies.18,39,40 The highest
category indicates most severe and most frequent insomnia symptoms.
Sleep duration was assessed with a single item: “About how many hours
of sleep did you get on a typical night during the past 4 weeks?” Response
categories included ≤5 h, 6 h, 7 h, 8 h, 9 h, ≥10 h. Due to the small number
of responses for 9 h and ≥10 h (4.4%), we combined these into one
category of ≥9 h.
WHI CT participants were scheduled to complete the WHIIRS at baseline,
year 1, and study closeout (on average, year 9). A random subsample of
participants were also scheduled to complete WHIIRS at year 3, year 6, and
year 9 of follow-up. The WHI OS participants were scheduled to complete
the measures at baseline and study closeout. For those participants
enrolled in the WHI extension studies, which began in 2005, the WHIIRS
was reassessed in 2011–2012. Measurements of sleep therefore occurred
at multiple time points in relation to cancer diagnosis.
Breast cancer diagnoses among WHI participants were self-reported
every 6 months to 1 year during study follow-up. All reported breast cancer
outcomes were conﬁrmed by medical record and pathology report review.
Final adjudication was performed at the clinical coordinating center using
the National Cancer Institute’s Surveillance, Epidemiology, and End Results
(SEER) coding system.
Fig. 3 Overall probability of depression by years from diagnosis. The
trend in depression levels changed following breast cancer
diagnosis (p < 0.01). The probability of depression went from 9.5%
at diagnosis to 6% about 20 years after diagnosis. Vertical center line
indicates breast cancer diagnosis time point.
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Covariates used in the analyses included age at enrollment, race/
ethnicity, income, education level, marital status, body mass index (BMI)
category, physical activity occurrences per week, current alcohol use, WHI
study arm (OS or CT), cancer stage at diagnosis (coded using SEER41), sleep
medications use, and depressive symptoms. Depression was assessed
using the Burnam 8-item scale for depressive disorders, which includes 6
items from the Center for Epidemiologic Studies Depression Scale (CES-D)
and 2 items from the Diagnostic Interview Schedule.42 The resulting
continuous score was converted into a binary variable using a 0.06 score
cutoff for depressive symptoms.42 For demographic variables with multiple
measurements, we chose to use the closest measurement to breast cancer
diagnosis without going past the diagnosis date. Age, race/ethnicity, and
education were collected at baseline only. Years from enrollment in WHI to
breast cancer diagnosis was calculated. Sleep measures were classiﬁed
with an indicator variable to signal whether they were collected before or
after breast cancer diagnosis.
The WHI offers a unique opportunity to address sleep quality and
duration differences among a diverse population of aging women. Women
were included in this analysis if they were: (1) diagnosed with invasive
breast cancer after WHI enrollment (n= 12,126); and (2) had at least one
completed WHIIRS and sleep duration assessment (n= 12, 098). Outcomes
data were assessed through September 2016 and covariate data were
collected through December 2015. Since we used mixed model analytic
methods that allow for incomplete observations, women were included in
our study sample even if they only had sleep measures before breast
cancer (n= 4342). This strategy captures a more diverse sample of
postmenopausal women diagnosed with breast cancer and greater
precision of estimates compared to an analysis restricted to participants
with both pre- and post-diagnosis measurements (n= 7706).
Statistical analysis
Baseline demographic and clinical characteristics of the study population
were calculated using means with standard deviations for continuous
variables and counts with percentages for categorical variables. χ2-tests
and one-way analysis of variance (ANOVA) were used to compare sleep
characteristics at baseline by race/ethnicity and age group. All statistical
tests were two-sided. We ﬁt a linear mixed effects model to the
longitudinal WHIIRS sleep quality data, containing slopes, which differed
by period (before and after diagnosis), to examine whether the trend in
WHIIRS sleep quality score over time changed following a cancer diagnosis.
The time scale for the analysis was years since diagnosis. The model
contained random- and ﬁxed-effects of time since diagnosis, period, and a
time-by-period interaction. The model assumed linear trends in sleep score
before and after cancer diagnosis, which seemed reasonable based on
LOWESS smoothed scatter plots of the data. We did not observe any
differences in variability from before to after diagnosis. A Wald test of the
ﬁxed interaction effect was used to determine whether there was a change
in trend following diagnosis. Additionally, we extended our model to
include depression to determine if a change in depressive symptoms could
explain the change in the WHIIRS sleep quality score.
To determine whether the change in trend of the WHIIRS scores post-
cancer diagnosis differed by subgroup (age at diagnosis, race/ethnicity,
cancer stage, education level, income level, BMI, physical activity, marital
status, or alcohol use), we extended the linear mixed model. A Wald test of
the three-way interaction was used to determine whether the change in
trend pre- to post-diagnosis differed by subgroup. Holm’s method was
used to correct for multiple three-way interaction tests for each outcome.43
Next, we ﬁt a logistic regression model for sleep duration with random
subject-speciﬁc intercepts accounting for the relationship between values
from the same subject. Due to the categorical responses of sleep duration,
we categorized sleep duration as a binary variable: As operationalized by
others33,44–46 participants were grouped according to those who slept <6 h
versus those who slept ≥6 h, to identify short sleepers and those who slept
<9 h versus ≥9 h, to identify long sleepers. As in the sleep quality analysis, the
sleep duration models contained ﬁxed effects of time since diagnosis, period,
and a time-by-period interaction, which was used to assess change in the
trend in sleep duration following diagnosis. These models were extended to
test for differences in change following breast cancer diagnosis by subgroup,
using the same approach implemented in the sleep quality analysis.
Finally, we conducted a sensitivity analysis to determine if the results
among women who had both pre- and post-diagnosis sleep measures (n
= 7706) differed from the results among the entire population (n=
12,098), which included women with only pre-diagnosis or only post-
diagnosis sleep measures (n= 4392).
All analyses were performed using SAS V9.4 (SAS Inc., Cary, NC) and
STATA 14 (StataCorp LP, College Station, TX).
Data availability
Data supporting the results of this paper can be requested from the
Women’s Health Initiative, https://www.whi.org/researchers/SitePages/
Home.aspx.
Code availability
Additional information, including statistical code, can be requested from
Chloe Beverly, Chloe.Beverly@osumc.edu.
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